Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 11/20 | 0.78 |
| ▸ | F2 | P00734 | 10/20 | 0.78 |
| ▸ | PLAT | P00750 | 10/20 | 0.78 |
| ▸ | PLG | P00747 | 10/20 | 0.78 |
| ▸ | F10 | P00742 | 4/20 | 0.71 |
| ▸ | KLK8 | O60259 | 4/20 | 0.71 |
| ▸ | KLK4 | Q9Y5K2 | 4/20 | 0.71 |
| ▸ | KLK2 | P20151 | 2/20 | 0.71 |
| ▸ | KLK1 | P06870 | 3/20 | 0.64 |
| ▸ | ELANE | P08246 | 2/20 | 0.53 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242610 | 0.93 | F2 (0.79) | PLAUF2PLATPLGF10 | |
| SCHEMBL2245991 | 0.90 | PLAU (0.71) | PLAUF2PLATPLGF10 | |
| SCHEMBL2247031 | 0.89 | PLAU (0.69) | PLAUF2PLATPLGF10 | |
| SCHEMBL21105298 | 0.88 | F2 (0.71) | PLAUF2PLATPLGF10 | |
| SCHEMBL12354626 | 0.88 | PLAU (1.00) | PLAUF2PLATPLGF10 | |
| SCHEMBL2244756 | 0.88 | F2 (0.59) | PLAUF2PLATPLGF10 | |
| SCHEMBL16144116 | 0.87 | PLAU (0.59) | PLAUF2PLATPLGF10 | |
| SCHEMBL7403534 | 0.87 | F2 (0.86) | PLAUF2PLATPLGF10 | |
| SCHEMBL12354620 | 0.87 | F2 (0.58) | PLAUF2PLATPLGF10 | |
| Hydrochloric Acid SCHEMBL13737965 | 0.86 | PLAU (0.58) | PLAUF2PLATPLGF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017527-B2 | KLK4 inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2018-07-10 | — | — | US | disclosed |
| US-10017527-B2 | KLK4 inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2018-07-10 | — | — | US | disclosed |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2017-04-13 | — | — | US | disclosed |
| WO-2015144933-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017527-B2 | KLK4 inhibitors | KLK4, KLK3, KLK1 | PLAU 1275/4885F2 4668/4885PLAT 1092/4885 |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | KLK4, KLK3, KLK1 | PLAU 1428/4885F2 4726/4885PLAT 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.